Psyence Biomed
The world’s first life science biotechnology company traded on the Nasdaq (NASDAQ:PBM) focused on the development of botanical (nature derived, or non-synthetic) psilocybin-based psychedelic medicines. The name “Psyence” combines the words “psychedelics” and “science” to affirm Psyence Biomed’s commitment to an evidence-based approach to innovation as it works to develop safe and effective, nature-derived psychedelic therapeutics to treat a broad range of mental health disorders. Psyence Biomed is initially focused on mental health disorders in the context of Palliative Care.
Psyence Biomed
The world’s first life science biotechnology company traded on the Nasdaq (NASDAQ:PBM) focused on the development of botanical (nature derived, or non-synthetic) psilocybin-based psychedelic medicines. The name “Psyence” combines the words “psychedelics” and “science” to affirm Psyence Biomed’s commitment to an evidence-based approach to innovation as it works to develop safe and effective, nature-derived psychedelic therapeutics to treat a broad range of mental health disorders. Psyence Biomed is initially focused on mental health disorders in the context of Palliative Care.
Our
Mission
Pioneering the use of natural
psychedelics for mental health
We are a life science biotechnology company developing innovative, safe and effective psychedelic and nature-centred solutions for mental health.
Our key focus area is palliative care. In particular, Psyence is targeting the indications of anxiety and depression, and associated ailments, within the context of palliative care.
Leading the Business of Medicine and Science
Working at the intersection of medicine, commerce, and science, our physician-led company is headed by R+D leader CEO Dr. Neil Maresky, MD. Our expertise in intellectual property and capital markets and business development brings a global track record of sustainable growth and shareholder value.
Our News
We believe in keeping our stakeholders informed and engaged with clear and timely communication. Whether it’s news about our scientific breakthroughs, regulatory updates, or leadership commentary, this is your trusted source for all formal communications from Psyence Biomed.
Our News
Psyence BioMed Chief of Global Impact to speak at Psychedelic Science 2025
Psyence BioMed’s Chief of Global Impact, Mary-Elizabeth Gifford, joins PS2025’s Business Track as a featured speaker at the world’s top psychedelic science event.
Psyence BioMed Regains Full Compliance with Nasdaq Continued Listing Requirements
Psyence Biomedical Ltd. announced that it has received formal notification from the Nasdaq Hearings Panel confirming that the Company has regained compliance with all applicable Nasdaq continued listing requirements. This confirmation follows a successful compliance hearing held on May 29, 2025.
Psyence BioMed Chief of Global Impact to speak at Psychedelic Science 2025
Investors, Entrepreneurs, and Industry Experts to Convene at the Premier Psychedelic Science Business Forum hosted by Multidisciplinary Association for Psychedelic Studies (MAPS)